Hematopoietic stem cell transplantation in T-prolymphocytic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation and the Royal Marsden Consortium
T-prolymphocytic leukemia (T-PLL) has a very poor prognosis with conventional immunochemotherapy. Incidental reports suggest that allogeneic hematopoietic stem cell transplantation (allo-HSCT) might have a role in this disease. Therefore, the purpose of the present study was to analyze the outcome o...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2012
|
| In: |
Leukemia
Year: 2011, Jahrgang: 26, Heft: 5, Pages: 972-976 |
| ISSN: | 1476-5551 |
| DOI: | 10.1038/leu.2011.304 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1038/leu.2011.304 Verlag, Volltext: https://www.nature.com/articles/leu2011304 
|
| Verfasserangaben: | W. Wiktor-Jedrzejczak, C. Dearden, L. de Wreede, A. van Biezen, L. Brinch, V. Leblond, M. Brune, L. Volin, M. Kazmi, A. Nagler, J. Schetelig, T. de Witte and P. Dreger |
| Zusammenfassung: | T-prolymphocytic leukemia (T-PLL) has a very poor prognosis with conventional immunochemotherapy. Incidental reports suggest that allogeneic hematopoietic stem cell transplantation (allo-HSCT) might have a role in this disease. Therefore, the purpose of the present study was to analyze the outcome of transplants for T-PLL registered with the European Group for Blood and Marrow Transplantation database and the Royal Marsden Consortium. Eligible were 41 patients with a median age of 51 (24-71) years; median time from diagnosis to treatment was 12 months, and in complete remission (CR) (11), partial remission (PR) (12), stable or progressive disease (13) and unknown in 5 patients. A total of 13 patients (31%) received reduced-intensity conditioning. Donors were HLA-identical siblings in 21 patients, matched unrelated donors in 20 patients. With a median follow-up of surviving patients of 36 months, 3-year relapse-free survival (RFS) and OS was 19% (95% CI, 6-31%) and 21% (95% CI, 7-34%), respectively. Multivariate analysis identified TBI and a short interval between diagnosis and HSCT as factors associated with favorable RFS. Three-year non relapse mortality and relapse incidence were each 41% with the majority of relapses occurring within the first year. These data indicate that allo-HSCT may provide effective disease control in selected patients with T-PLL. |
|---|---|
| Beschreibung: | Published online: 25 November 2011 Gesehen am 14.05.2018 |
| Beschreibung: | Online Resource |
| ISSN: | 1476-5551 |
| DOI: | 10.1038/leu.2011.304 |